Quantcast

Latest Bevacizumab Stories

2014-05-16 12:27:57

RnRMarketResearch.com adds "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies" to its store. DALLAS, May 16, 2014 /PRNewswire-iReach/ -- "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies". The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately...

2014-05-16 08:26:16

30mg/m2 dose cohort had been completed; enrollment of 40mg/m2 cohort has been initiated VANCOUVER, British Columbia and MENLO PARK, Calif., May 16, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") is pleased to provide an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma multiforme (GBM). DelMar has completed enrollment of VAL-083 dose Cohort 6 and advanced to Cohort 7. DelMar most recently presented...

2014-05-07 23:00:23

ResearchMoz.us include new market research report "Ovarian Cancer Therapeutics to 2020" to its huge collection of research reports. Get Detail Report With TOC at http://www.researchmoz.us/ovarian-cancer-therapeutics-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-survival-and-targeted-therapies-report.html. Albany, New York (PRWEB) May 08, 2014 Researchmoz presents this most up-to-date research on "Ovarian Cancer Therapeutics to 2020 - Late-Stage Pipeline...

2014-05-07 12:26:55

Roche/Genentech's Avastin Continues to Garner the Greatest Physician-Reported Patient Share in DME Due to Its Low Relative Cost, According to Findings from Decision Resources Group BURLINGTON, Mass., May 7, 2014 /PRNewswire/ -- Decision Resources Group finds that, ahead of the anticipated label expansion of Regeneron's Eylea for diabetic macular edema (DME) in August 2014, over half of surveyed U.S. retinal specialists and general ophthalmologists currently prescribe this anti-vascular...

2014-05-05 20:23:52

LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/renal_cell_carcinoma_global_clinical_trials_review.htmlRenal Cell Carcinoma Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Renal Cell Carcinoma...

2014-05-05 08:29:46

SAN DIEGO, May 5, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin(®) (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers. The open-label study is expected to enroll up to 64...

2014-05-01 08:34:14

MM-398 in Combination with 5-FU and Leucovorin Provides New Treatment Option for Patients Previously Treated with Gemcitabine MANHATTAN BEACH, Calif., May 1, 2014 /PRNewswire/ -- The Pancreatic Cancer Action Network is pleased to announce that today Merrimack Pharmaceuticals, Inc., (Merrimack) reported a 1.9 month improvement in survival for patients treated with the combination of its drug, MM-398, with 5-fluorouracil (5-FU) and leucovorin. According to Merrimack, the NAPOLI-1...

2014-04-21 20:21:44

INDIANAPOLIS, April 21, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA(TM) (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. With this approval, CYRAMZA becomes the first FDA-approved treatment for patients...

2014-04-09 12:31:10

VAL-083 therapy is well tolerated to date; dose limiting toxicity has not been reached after fifth cohort (20mg/m2) VANCOUVER, British Columbia and MENLO PARK, Calif., April 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced an update on its ongoing Phase I/II clinical trial with VAL-083 in the treatment of refractory glioblastoma multiforme (GBM). The company's new data are being presented in a poster entitled, "A Phase I/II Study of VAL-083 in...

2014-04-08 23:02:54

New research report “Biosimilar Index: Tracking the Global Biosimilar Pipeline” worked out by FirstWord is now available at MarketPublishers.com London, UK (PRWEB) April 08, 2014 At present, biosimilars and non-comparable biologics (NCBs) are being developed across thirteen discreet therapy areas. There exist around 40 biosimilar and NCB programmes currently in Phase III trials. Moreover, it is known that there are fifteen biosimilar and NCB versions of bevacizumab (Avastin, Roche)...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related